Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Vitamin B9 and Reduced Homocysteine Level

Research synthesisHigh evidenceMixed effect size7 studies · 6 beneficial · 1 neutral · 0 harmful

Across 7 studies, 6 reported beneficial effects of Vitamin B9 supplementation on reducing homocysteine levels, with a predominant effect size ranging from small to moderate. Most evidence comes from randomized controlled trials and meta-analyses in clinical populations (e.g., coronary heart disease, type 2 diabetes) and healthy adults, with doses typically around 1 mg/day and effects observed at 8–12 weeks. The median study duration was 84 days, indicating sustained supplementation is typical for achieving reductions.

  • Effective dose range: 1 mg/day
  • Studied populations: healthy adults, patients with coronary heart disease, patients with type 2 diabetes, older adults (50–65 years)

Caveats: BeneficialCount is 6 of 7 (≥85%) — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). One neutral study in children with sickle cell disease suggests the effect may not generalize to pediatric populations or those with certain comorbidities. Most trials were relatively short (4–12 weeks); longer-term effects are less documented.

Generated Jul 9, 2026
Doses used in studies
  • mg/day: 1 (median 1, IQR 11) 2 studies
  • mcg/day: 400 (median 400, IQR 400400) 1 study
Time to effect
Median: 2.8 months · IQR 8 weeks2.8 months · Range 4 weeks2.8 months — Reported in 3 of 7 studies
Safety in these studies
7 of 7 papers
Back to top